Blood-pressure reduction is the only proven treatment to prevent stroke. Whether a single pill that combines three ...

Explore this issue of The New England Journal of Medicine (Vol. 394 No. 1).

Explore this issue of The New England Journal of Medicine (Vol. 394 No. 7).

Explore this issue of The New England Journal of Medicine (Vol. 392 No. 10).

Guidelines recommend a trial of antiarrhythmic drugs before catheter ablation for persistent atrial fibrillation. Whether pulsed field ablation (PFA) may be a preferred initial treatment is ...

Over the past few years, U.S. academic medical centers have faced a revolution in medical training, with major shifts in trainees’ values, attitudes toward work and education, and demands for change.

Explore this issue of The New England Journal of Medicine (Vol. 393 No. 24).

Explore this issue of The New England Journal of Medicine (Vol. 393 No. 14).

Explore the current issue of The New England Journal of Medicine (Vol. 394 No. 17).

The author describes the scientific foundations and implications of the results of a randomized, controlled trial of Mim8, a new mimetic of factor VIIIa, to treat hemophilia A.

Overactivation of the alternative complement pathway contributes to IgA nephropathy and glomerular inflammation. In the 9-month interim analysis of this phase 3 trial, iptacopan, a complement factor B ...